LiDCO Group Plc
09 May 2005

                                LiDCO GROUP PLC

                           ("LiDCO" or "the Company")

    Product Registration in Brazil - Largest Medical Market in Latin America


LiDCO Group plc (AIM: LID), the UK-based cardiovascular monitoring company, is
pleased to announce today that registration of the LiDCOplus Monitor, associated
disposables and lithium chloride injection have been approved for sale in
Brazil. Brazil is the largest medical market in Latin America with around 7,200
hospitals and an estimated hospital services market of $5 billion.

The full launch of LiDCO's products in Brazil will take place at the 3rd
International Symposium on Intensive Care & Emergency Medicine for Latin
America, June 21- 25th in Sao Paulo.

Terry O'Brien, Chief Executive of LiDCO, stated: "Brazil is the biggest Latin
American market for our products. This is the fifth  additional country that we
have added to our sales territories in 2005. We expect the successful conclusion
to these registration activities will contribute to further sales growth during
the year."

Mario Padovani, Managing Director of LiDCO's Brazilian distributor, Bragenix,
said: "I am delighted that the LiDCO products have been approved for sale. This
is especially good timing because the recently published trial results showing
major reductions in surgical complications obtained at St George's Hospital will
be presented at our June critical care symposium in Sao Paulo. We are excited
about developing a very strong market for LiDCO's products in Brazil."

For further information please contact:

LiDCO Group Plc
Terry O'Brien (CEO) terry@lidco.com                                020 7749 1500
Hugh McGarel-Groves (FD)     hugh.mcgarelgroves@lidco.com

Buchanan Communications
Tim Anderson, Mary-Jane Johnson, James Strong                      020 7466 5000


Notes for Editors


About LiDCO Plc

LiDCO is a UK-based AIM-traded developer, manufacturer and leading supplier of
minimally invasive, computer-based hemodynamic monitoring equipment and
disposables used primarily for the management of critical care and
cardiovascular risk hospital patients. Use of LiDCO's technology has been shown
to significantly reduce the complications (particularly infections) and costs
associated with major surgery The technology was invented in the Department of
Applied Physiology based at St Thomas' Hospital, London where the Company
maintains a research base.


The Company's manufacturing facility is in Hoxton, London and its current
products are:

  •  LiDCOplus and PulseCO monitors: computer-based platforms for displaying a
     range of real-time, continuous hemodynamic parameters including cardiac 
     output, oxygen delivery and fluid volume;

  •  LiDCO disposables: used in conjunction with the LiDCOplus Monitor
     accurately determine cardiac output in a minimally-invasive manner.


Distribution Network:

Following today's announcement the Company has now achieved registration of its
products in 13 markets in Europe, the USA, Brazil and Japan.  It sells direct to
the NHS in the UK, and through a worldwide network of specialty critical care
distributors.


Background to the recently published clinical trial: Better than standard care -
(EGDT) improves outcome in high risk surgery patients:

The results of a major trial at St George's Hospital, London using LiDCO's
minimally invasive monitoring technology were presented during the 25th
International Symposium on Intensive Care and Emergency Medicine in Brussels
(21st to 25th March). The results have revealed the following:

  a) Savings in the cost of treating patients amounting to an average of £4,000
  per patient.  Extrapolated nationally, this would equate to a saving of £500
  million per annum for the NHS

  b) The monetary saving (£248,000) - resulted from 640 hospital days saved for 
  62 patients, an average of more than 10 bed days per patient

  c) The savings in cost and hospital days were associated with a significant
  reduction in medical complications (particularly infections - which were 
  halved) through the use of LiDCO's minimally invasive technology to improve 
  tissue oxygen levels following surgery.


                      This information is provided by RNS
            The company news service from the London Stock Exchange